Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.

IF 3.5 2区 医学 Q2 ONCOLOGY
Atena Najdian, Davood Beiki, Milad Abbasi, Ali Gholamrezanezhad, Hojjat Ahmadzadehfar, Ali Mohammad Amani, Mehdi Shafiee Ardestani, Majid Assadi
{"title":"Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.","authors":"Atena Najdian, Davood Beiki, Milad Abbasi, Ali Gholamrezanezhad, Hojjat Ahmadzadehfar, Ali Mohammad Amani, Mehdi Shafiee Ardestani, Majid Assadi","doi":"10.1186/s40644-024-00762-z","DOIUrl":null,"url":null,"abstract":"<p><p>Multimodal imaging unfolds as an innovative approach that synergistically employs a spectrum of imaging techniques either simultaneously or sequentially. The integration of computed tomography (CT), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and optical imaging (OI) results in a comprehensive and complementary understanding of complex biological processes. This innovative approach combines the strengths of each method and overcoming their individual limitations. By harmoniously blending data from these modalities, it significantly improves the accuracy of cancer diagnosis and aids in treatment decision-making processes. Nanoparticles possess a high potential for facile functionalization with radioactive isotopes and a wide array of contrast agents. This strategic modification serves to augment signal amplification, significantly enhance image sensitivity, and elevate contrast indices. Such tailored nanoparticles constructs exhibit a promising avenue for advancing imaging modalities in both preclinical and clinical setting. Furthermore, nanoparticles function as a unified nanoplatform for the co-localization of imaging agents and therapeutic payloads, thereby optimizing the efficiency of cancer management strategies. Consequently, radiolabeled nanoparticles exhibit substantial potential in driving forward the realms of multimodal imaging and theranostic applications. This review discusses the potential applications of molecular imaging in cancer diagnosis, the utilization of nanotechnology-based radiolabeled materials in multimodal imaging and theranostic applications, as well as recent advancements in this field. It also highlights challenges including cytotoxicity and regulatory compliance, essential considerations for effective clinical translation of nanoradiopharmaceuticals in multimodal imaging and theranostic applications.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416024/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-024-00762-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multimodal imaging unfolds as an innovative approach that synergistically employs a spectrum of imaging techniques either simultaneously or sequentially. The integration of computed tomography (CT), magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), and optical imaging (OI) results in a comprehensive and complementary understanding of complex biological processes. This innovative approach combines the strengths of each method and overcoming their individual limitations. By harmoniously blending data from these modalities, it significantly improves the accuracy of cancer diagnosis and aids in treatment decision-making processes. Nanoparticles possess a high potential for facile functionalization with radioactive isotopes and a wide array of contrast agents. This strategic modification serves to augment signal amplification, significantly enhance image sensitivity, and elevate contrast indices. Such tailored nanoparticles constructs exhibit a promising avenue for advancing imaging modalities in both preclinical and clinical setting. Furthermore, nanoparticles function as a unified nanoplatform for the co-localization of imaging agents and therapeutic payloads, thereby optimizing the efficiency of cancer management strategies. Consequently, radiolabeled nanoparticles exhibit substantial potential in driving forward the realms of multimodal imaging and theranostic applications. This review discusses the potential applications of molecular imaging in cancer diagnosis, the utilization of nanotechnology-based radiolabeled materials in multimodal imaging and theranostic applications, as well as recent advancements in this field. It also highlights challenges including cytotoxicity and regulatory compliance, essential considerations for effective clinical translation of nanoradiopharmaceuticals in multimodal imaging and theranostic applications.

探索放射性标记纳米粒子在癌症多模式成像和治疗应用方面的创新进展。
多模态成像是一种创新方法,可同时或依次协同使用一系列成像技术。将计算机断层扫描(CT)、磁共振成像(MRI)、单光子发射计算机断层扫描(SPECT)、正电子发射计算机断层扫描(PET)和光学成像(OI)整合在一起,可以全面、互补地了解复杂的生物过程。这种创新方法结合了每种方法的优势,克服了它们各自的局限性。通过和谐地融合这些模式的数据,可显著提高癌症诊断的准确性,并有助于治疗决策过程。纳米粒子具有很大的潜力,可与放射性同位素和各种造影剂进行简单的功能化。这种策略性修饰可增强信号放大效果,显著提高图像灵敏度,并提升对比度指数。这种量身定制的纳米粒子结构为临床前和临床成像模式的发展提供了广阔的前景。此外,纳米颗粒还可作为成像剂和治疗载荷共定位的统一纳米平台,从而优化癌症治疗策略的效率。因此,放射性标记纳米粒子在推动多模式成像和治疗应用领域的发展方面展现出巨大的潜力。本综述讨论了分子成像在癌症诊断中的潜在应用、基于纳米技术的放射性标记材料在多模式成像和治疗应用中的利用,以及该领域的最新进展。它还强调了包括细胞毒性和监管合规性在内的挑战,以及在多模态成像和治疗应用中有效临床转化纳米放射性药物的基本考虑因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Imaging
Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
7.00
自引率
0.00%
发文量
66
审稿时长
>12 weeks
期刊介绍: Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信